-+ 0.00%
-+ 0.00%
-+ 0.00%

Cypherpunk unit Leap publishes Phase 2 DeFianCe data on sirexatamab in second-line metastatic colorectal cancer

PUBT·08/12/2026 11:03:59
Listen to the news
Cypherpunk unit Leap publishes Phase 2 DeFianCe data on sirexatamab in second-line metastatic colorectal cancer
  • Cypherpunk Technologies reported peer-reviewed publication of Phase 2 DeFianCe trial results for sirexatamab in second-line metastatic colorectal cancer.
  • Results were presented in the new journal publication, not as a future conference readout.
  • Overall study readout was mixed, with the main population falling short of the trial’s primary goal.
  • Benefit appeared concentrated in patients with higher baseline plasma DKK1, supporting a biomarker-selected Phase 3 strategy.
  • Safety profile broadly matched standard therapy, with no meaningful new tolerability signal from adding sirexatamab.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cypherpunk Technologies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE24369) on August 12, 2026, and is solely responsible for the information contained therein.